This clinical trial studies how well fludeoxyglucose F-18 positron emission tomography (PET)/magnetic resonance imaging (MRI) works in assessing treatment response in patients with nasopharyngeal cancer who are receiving chemoradiotherapy. PET uses radiation and MRI uses magnetic fields to create images to provide us information about the structure, function, and metabolism (level of activity and use of nutrients) of different tissues in the body, and may help provide accurate assessment of treatment response.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03656250.
PRIMARY OBJECTIVES:
I. To determine if the glucose metabolic rate (GMR) measured by PET/magnetic resonance (MR) after the first stage of treatment is lower in complete responders than in non-complete responders.
SECONDARY OBJECTIVES:
I. To determine whether the GMR measured by PET/MR immediately after the treatment can be used to assess presence of residual tumor in comparison with PET/MR evaluation 3 month after completion of treatment.
OUTLINE:
Patients receive fludeoxyglucose F-18 intravenously (IV) and undergo PET/MR over 40-60 minutes immediately after the first stage of treatment and after the second stage if the 3 month chemotherapy is given. Patients may also receive fludeoxyglucose F-18 IV and within 90 minutes undergo PET/computed tomography (CT) at baseline and after the second PET/MR.
Trial PhaseNo phase specified
Trial Typediagnostic
Lead OrganizationLaura and Isaac Perlmutter Cancer Center at NYU Langone
Principal InvestigatorSungheon Gene Kim
